# ICU Medical Inc: Form 10-Q for the period ended Mar 31, 2019

- Company: [ICU Medical Inc](/companies/icui.md) (CIK 883984)
- Form: 10-Q
- Filed: 2019-05-10
- Accepted by EDGAR: May 10, 2019, 16:04 ET
- Period: 2019-03-31
- Accession: 0000883984-19-000017
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/883984/000088398419000017/icui0331201910-q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/883984/000088398419000017/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2019-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2019-01-01 to 2019-03-31 | $330.9m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2019-01-01 to 2019-03-31 | $195.6m | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2019-01-01 to 2019-03-31 | $135.3m | us-gaap:GrossProfit |
| Research and development | 3 months, 2019-01-01 to 2019-03-31 | $12.8m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2019-01-01 to 2019-03-31 | $72.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2019-01-01 to 2019-03-31 | $30.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2019-01-01 to 2019-03-31 | $133.0k | us-gaap:InterestExpense |
| Income tax | 3 months, 2019-01-01 to 2019-03-31 | $2.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2019-01-01 to 2019-03-31 | $31.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2019-01-01 to 2019-03-31 | $1.44 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2019-01-01 to 2019-03-31 | $1.51 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2019-01-01 to 2019-03-31 | 21,551,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2019-01-01 to 2019-03-31 | −$21.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2019-01-01 to 2019-03-31 | $28.7m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2019-03-31 | $296.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2019-03-31 | $920.5m | us-gaap:AssetsCurrent |
| Total assets | at 2019-03-31 | $1.61bn | us-gaap:Assets |
| Current liabilities | at 2019-03-31 | $238.4m | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | at 2019-03-31 | $1.28bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 41,651 characters.

The following information should be read in conjunction with the condensed consolidated financial statements and accompanying notes in this Form 10-Q, as well as the audited consolidated financial statements and related notes for the fiscal year ended December 31, 2018 included in our Annual Report on Form 10-K.

When used in this report, the terms “we,” “us,” and “our” refer to ICU Medical, Inc ("ICU") and its subsidiaries included in our condensed consolidated financial statements unless context requires otherwise.

### Overview

We are one of the world's leading pure-play infusion therapy companies with global operations and a wide-ranging product portfolio that includes IV solutions, IV smart pumps with pain management and safety software technology, dedicated and non-dedicated IV sets and needlefree connectors designed to help meet clinical, safety and workflow goals. In addition, we manufacture automated pharmacy IV compounding systems with workflow technology, closed systems transfer devices for preparing and administering hazardous IV drugs, and cardiac monitoring systems for critically ill patients.

Our primary customers are acute care hospitals, wholesalers, ambulatory clinics and alternate site facilities, such as clinics, home health care providers and long-term care facilities. We sell our products in more than 90 countries throughout the world.

We categorize our products into four main product lines: Infusion Consumables, IV Solutions, Infusion Systems, and Critical Care. We have presented our financial results in accordance with these product lines, with our primary products in each line listed below.

### Infusion Consumables

Infusion therapy sets, used in hospitals and ambulatory clinics, consist of a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patient’s vein, that may or may not be used with an IV pump. Our primary Infusion Consumable products are:

- *Clave™ needlefree products*, including the MicroClave, MicroClave Clear, and NanoClave™ brand of connectors, accessories, extension and administration sets used for the administration of IV fluids and medications and the Neutron catheter patency device, used to help maintain patency of central venous catheters;
- *SwabCap* disinfecting cap, used to protect and disinfect any needlefree connector, including competitive brands of connectors;
- *Tego* hemodialysis connector used to cap and protect hemodialysis central venous catheter hubs; and
- *NovaCath™ and SuperCath™* peripheral IV catheters (PIV).

*Closed System Transfer Devices (CSTD) and hazardous drug compounding systems* are used to prepare and deliver hazardous IV medications such as those used in chemotherapy, which, if released, can have harmful effects on the healthcare worker and environment. Our products are:

- *ChemoLock* CSTD with a proprietary and pharmacy-preferred needlefree connection method, used for the preparation and administration of hazardous drugs. ChemoLock is used to limit the escape of hazardous drug or vapor concentrations, blocks the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury;
- *ChemoClave*, an ISO Connection standard and universally compatible CSTD used for the preparation and administration of hazardous drugs. ChemoClave utilizes standard ISO luer locking connections, making it compatible with all brands of needlefree connectors and pump delivery systems. ChemoClave also limits the escape of hazardous drug or vapor concentrations, blocks the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; and
- *Diana* hazardous drug compounding system, an automated sterile compounding system that incorporates ChemoClave and ChemoLock CSTD consumables and IV workflow technology for the accurate, safe, and efficient preparation of hazardous drugs. It is a user-controlled automated system that provides repeatable accuracy of drug mixes and minimizes clinician exposure to hazardous drugs while helping to maintain the sterility of the drugs being mixed.

The preparation of hazardous drugs typically takes place in a pharmacy location where drugs are removed from vials and prepared for delivery to a patient. Those prepared drugs are then transferred to a nursing unit where the chemotherapy is administered via an infusion pump set to a patient. Components of the ChemoClave and ChemoLock product lines are used both in pharmacies and on the nursing floors for the preparation and administration of hazardous drugs.

### IV Solutions

We provide a broad portfolio of IV solutions to meet our customers’ clinical needs, providing a consistent supply of IV solutions, irrigation, and nutritionals to help provide safe and effective patient care. Our primary IV Solutions products are:

#### IV Therapy and Diluents:

- Including Sodium Chloride, Dextrose, Balanced Electrolyte Solutions, Lactated Ringer's, Ringer's, Mannitol, Sodium Chloride/Dextrose and Sterile Water

#### Irrigation/Urologics:

- Including Sodium Chloride Irrigation, Sterile Water Irrigation, Physiologic Solutions, Ringer's Irrigation, Ringer's Irrigation, Acetic Acid Irrigation, Glycine Irrigation, Sorbitol-Mannitol Irrigation, Flexible Containers and Pour Bottle Options

### Infusion Systems

We offer a wide range of infusion pumps, dedicated IV sets and software. Our primary Infusion System products are dedicated IV sets and the following:

#### Infusion Pump Hardware:

- *Plum 360™:* The Plum 360™ infusion pump is an ICU Medical MedNet™ ready large volume infusion pump with an extensive drug library and wireless capability. Plum 360 was named the 2018 Best in KLAS winner as top-performing IV smart pump and is the first medical device to be awarded UL Cybersecurity Assurance Program Certification; and
- *LifeCare PCA™*: The LifeCare PCA infusion pump is an ICU Medical MedNet™ ready patient-controlled analgesia pump (PCA), providing complete IV-EHR interoperability since 2016.

#### IV Mediation Safety Software:

- *ICU Medical MedNet™*: ICU Medical MedNet is an enterprise-class medication management platform for any sized healthcare system that can help reduce medication errors, improve quality of care, streamline workflows and maximize revenue capture. ICU Medical MedNet connects our industry-leading smart pumps to a hospital’s Electronic Health Records (EHR), asset tracking systems, and alarm notification platforms with the largest array of integration partners.

#### Professional Services:

- In addition to the products above, our teams of clinical, information technology, and professional services experts work with customers to develop and deliver safe and efficient infusion systems, providing customized and personalized configuration, implementation, and data analytics services to complement our infusion hardware and software.

### Critical Care

Our Critical Care products help clinicians get accurate real-time access to patients’ hemodynamic and cardiac status with an extensive portfolio of monitoring systems and advanced sensors & catheters. Measurements provided by our systems help clinicians determine how well the heart is pumping blood and how efficiently oxygen from the blood is being used by the tissues. Our primary Critical Care products are:

- Cogent™ 2-in-1 hemodynamic monitoring system
- CardioFlo™ hemodynamic monitoring system
- TDQ™ and OptiQ™ cardiac output monitoring catheters
- Transpac™ blood pressure transducers
- SafeSet™ closed blood sampling and conservation system

The following table summarizes our total worldwide revenue by domestic and international markets by amount and as a percentage of total revenue (in millions, except percentages):

|  | Three months ended March 31, 2019 $% of Revenue |  | 2018 $% of Revenue |  |
| --- | ---: | ---: | ---: | ---: |
| Domestic | $247.2 | 75% | $281.6 | 76% |
| International | 83.7 | 25% | 90.4 | 24% |
| Total Revenue | $330.9 | 100% | $372.0 | 100% |

The following table sets forth, for the periods indicated, total revenue by product line as a percentage of total revenue:

| Product line | Three months ended March 31, 2019 | 2018 |
| --- | ---: | ---: |
| Infusion Consumables | 36% | 32% |
| IV Solutions | 34% | 39% |
| Infusion Systems | 26% | 25% |
| Critical Care | 4% | 4% |
|  | 100% | 100% |

We manage our product distribution in the U.S. through a network of three owned distribution facilities, as well as, through direct channels, which include independent distributors and the end users of our products, and as original equipment manufacturer suppliers. Most of our independent distributors handle the full line of our products. Internationally, we manage our operations through the Netherlands, which utilizes international regional hubs. We also manage our operations through independent distributors.

A substantial amount of our products are sold to Group Purchasing Organization member hospitals. We believe that as healthcare providers continue to either consolidate or join major buying organizations, the success of our products will depend, in part, on our ability, either independently or through strategic relationships to secure long-term contracts with large healthcare providers and major buying organizations. Although we believe that we are not dependent on any single distributor for distribution of our products, the loss of a strategic relationship with a customer could have a material adverse effect on our operating results.

We believe that achievement of our growth objectives worldwide will require increased efforts by us in sales and marketing and product acquisition and development; however, there is no assurance that we will be successful in implementing our growth strategy. Product development or acquisition efforts may not succeed, and even if we do develop or acquire additional products, there is no assurance that we will achieve profitable sales of such products. Increased expenditures for sales and marketing and product acquisition and development may not yield desired results when expected, or at all. While we have taken steps to control these risks, there are certain risks that may be outside of our control, and there is no assurance that steps we have taken will succeed.

### Seasonality/Quarterly Results

There are no significant seasonal aspects to our business. We may experience fluctuations in net sales as a result of variations in the ordering patterns of our largest customers, which may be driven more by production scheduling and their inventory levels, and less by seasonality. Our expenses often do not fluctuate in the same manner as net sales, which may cause fluctuations in operating income that are disproportionate to fluctuations in our revenue.

### Consolidated Results of Operations

We present income statement data in Part I, Item 1 - Financial Statements. The following table shows, for the three ended March 31, 2019 and 2018, the percentages of each income statement caption in relation to total revenue:

|  | Three months ended March 31, 2019 | 2018 |
| --- | ---: | ---: |
| Total revenue | 100% | 100% |
| Gross margin | 41% | 40% |
| Selling, general and administrative expenses | 22% | 23% |
| Research and development expenses | 4% | 3% |
| Restructuring and strategic transaction | 7% | 6% |
| Change in fair value of contingent earn-out | (2)% | (1)% |
| Contract settlement | 1% | 8% |
| Total operating expenses | 32% | 39% |
| Income from operations | 9% | 1% |
| Interest expense | —% | —% |
| Other income, net | 1% | —% |
| Income before income taxes | 10% | 1% |
| (Provision) Benefit for income taxes | (1)% | —% |
| Net income | 9% | 1% |

In addition to comparing changes in revenue on a U.S. GAAP basis, we also compare the changes in revenue from one period to another using constant currency. We provide constant currency information to enhance the visibility of underlying business trends, excluding the effects of changes in foreign currency translation rates. To calculate our constant currency results, we apply the average exchange rate for revenues from the prior year to the current year results. These results should be considered in addition to, not as a substitute for, results reported in accordance with GAAP. Results on a constant currency basis, as we present them, may not be comparable to similarly titled measures used by other companies and are not measures of performance presented in accordance with GAAP.

### Infusion Consumables

The following table summarizes our total Infusion Consumables revenue (in millions):

|  | Three months ended March 31, 2019 | 2018 | $ Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| Infusion Consumables | $120.5 | $119.9 | $0.6 | 0.5% |

Infusion Consumables revenue slightly increased for the three months ended March 31, 2019, as compared to the same period in the prior year. We only had a slight increase primarily due to temporary supply constraints in our oncology products. Infusion Consumables revenue was also impacted by exchange rate changes. On a constant currency basis, Infusion Consumables revenue would have been $123.7 million for the three months ended March 31, 2019, an increase of $3.8 million or 3.2%, as compared to the same period in the prior year.

### IV Solutions

The following table summarizes our total IV Solutions revenue (in millions):

|  | Three months ended March 31, 2019 | 2018 | $ Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| IV Solutions | $113.2 | $144.4 | $(31.2) | (21.6)% |

IV Solutions sales decreased for the three months ended March 31, 2019, as compared to the same period in the prior year. Supply constraints from our competitors beginning in the second quarter of 2017 and continuing through the first half of 2018 caused some temporary customer purchases and stock-up on supplies of IV Solutions in the three months ended March 31, 2018. These market shortages temporarily drove up the demand for our product during that period.

### Infusion Systems

The following table summarizes our total Infusion Systems revenue (in millions):

|  | Three months ended March 31, 2019 | 2018 | $ Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| Infusion Systems | $84.3 | $93.4 | $(9.1) | (9.7)% |

Infusion Systems revenue decreased for the three months ended March 31, 2019, as compared to the same period in the prior year, primarily due to historical losses in our U.S. installed base of infusion pumps and due to the impact of exchange rate changes. On a constant currency basis Infusion Systems revenue would have been $87.9 million for the three months ended March 31, 2019, a decrease of $5.5 million or 5.9%, as compared to the same period in the prior year.

### Critical Care

The following table summarizes our total Critical Care revenue (in millions):

|  | Three months ended March 31, 2019 | 2018 | $ Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| Critical Care | $12.9 | $14.3 | $(1.4) | (9.8)% |

Critical Care revenue decreased for the three months ended March 31, 2019, as compared to the same period in the prior year, primarily due to the timing of orders.

### Gross Margins

For the three months ended March 31, 2019 and 2018, gross margins were 40.9%, and 40.1%, respectively. The increase in gross margin for the three months ended March 31, 2019, as compared to the same period in the prior year is primarily due Infusion Consumables increasing as a portion of our product mix and increased factory efficiencies.

### Selling, General and Administrative (“SG&A”) Expenses

The following table summarizes our total SG&A Expenses (in millions):

|  | Three months ended March 31, 2019 | 2018 | $ Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| SG&A | $72.6 | $85.0 | $(12.4) | (14.6)% |

SG&A expenses decreased for the three months ended March 31, 2019 as compared to the same period in the prior year. Consulting expense decreased $10.3 million, legal expense decreased $2.6 million, and compensation expense decreased $1.6 million. Partially offsetting these decreases was a $1.9 million increase in depreciation expense and a $1.8 million increase bad debt and warranty expense. Consulting expenses decreased as our transitional services agreement with Pfizer ended in the fourth quarter of 2018. Legal expenses were higher in the prior year due to expenses incurred related to the contract settlement, discussed below. Compensation expense decreased in the current period as incentive bonuses were higher in the prior year due to the integration of the HIS business. Depreciation expense increased due to an increase in the depreciable asset base. Bad debt expense increased primarily due to the quarterly assessment of our reserves related to our accounts receivable.

We reclassified $2.0 million of foreign exchange losses from SG&A for the three months ended March 31, 2018 to other income (expense), net to conform to our current year reporting of those gains and losses, see below, other income (expense), net.

### Research and Development (“R&D”) Expenses

The following table summarizes our total R&D Expenses (in millions):

|  | Three months ended March 31, 2019 | 2018 | $ Change | % Change |
| --- | ---: | ---: | ---: | ---: |
| R&D | $12.8 | $12.6 | $0.2 | 1.6% |

R&D expenses slightly increased for the three months ended March 31, 2019, as compared to the same period in the prior year. The current year expense is primarily related to compensation and benefit expenses incurred on our current R&D projects.

### Restructuring and Strategic Transaction and Integration Expenses

Restructuring and strategic transaction and integration expenses were $24.4 million and $21.6 million for the three months ended March 31, 2019 and 2018, respectively. For the three months ended March 31, 2019, the restructuring and strategic transaction and integration expenses were primarily related to our final Pfizer separation costs and clean-up, which included a $12.7 million non-cash write-off of related assets.

#### Restructuring charges

Restructuring charges were $0.8 million and $1.8 million for the three months ended March 31, 2019 and 2018, respectively. These charges were related to the integration of our acquired Hospira Infusion Systems ("HIS") business. We expect to pay unpaid restructuring charges as of March 31, 2019, by the end of 2019.

#### Strategic transaction and integration expenses

Strategic transaction and integration expenses were $23.6 million and $19.8 million for the three months ended March 31, 2019 and 2018, respectively, primarily related to our integration of the HIS business.

### Change in Fair Value of Earn-out

The fair value revaluation of our HIS contingent earn-out liability resulted in a decreases of value of $7.7 million and $4.0 million for the three months ended March 31, 2019 and 2018, respectively.

### Contract Settlement

For the three months ended March 31, 2019, and 2018 we incurred an expense of $2.9 million and $28.9 million, respectively, related to the resolution of a dispute with a product partner, which resulted in a redefinition of our contractual arrangement and in the rights and remedies determined under such arrangement.

### Interest Expense

Interest expense was $0.1 million for the three months ended March 31, 2019 and 2018. The interest expense for both periods is related to the amortization of financing costs incurred as of year-end December 31, 2017, in connection with a five-year Revolving Credit Facility and a related per annum commitment fee charged on the unused portion of the revolver under such Credit Facility (see Note 17: Long-Term Obligations in our accompanying condensed consolidated financial statements for additional information).

### Other Income (Expense), net

Other income (expense), net was $3.2 million and ($1.0) million for the three months ended March 31, 2019 and 2018, respectively. In 2019, we reported foreign exchange gains and losses in other income (expense), net, accordingly for comparative purposes we reclassified prior year's foreign exchange gains and losses to other income (expense), net from SG&A. For the three months ended March 31, 2019, net foreign exchange gains were $1.3 million, as compared to a net foreign exchange loss of $2.0 million for the three months ended March 31, 2018.

### Income Taxes

For the three months ended March 31, 2019 and 2018, income taxes were accrued at an estimated effective tax rate of 7% and (28)%, respectively.

The effective tax rate for the three months ended March 31, 2019 differs from the federal statutory rate of 21% principally because of the effect of the mix of U.S. and foreign incomes, state income taxes, global intangible low-taxed income (GILTI) and tax credits. It is also affected by discrete items that may occur in any given year but are not consistent from year to year. The effective tax rate during the three months ended March 31, 2019 included a tax benefit of $5.6 million related to the excess tax benefits recognized on stock option exercises and the vesting of restricted stock units during the period, which is treated as a discrete item and excluded from determining our annual estimated effective tax rate. In addition, a revaluation of the contingent consideration resulted in a tax provision of $1.8 million for the three months ended March 31, 2019, which was treated as a discrete item.

The effective tax rate for the three months ended March 31, 2018 differs from the federal statutory rate of 21% principally because of the effect the mix of U.S. and foreign incomes, state income taxes, tax credits and impact of a contract settlement. The contract settlement resulted in a material tax benefit of $5.7 million, which is treated as a discrete item. The effective tax rate during the three months ended March 31, 2018 also included a material tax benefit of $3.4 million related to the excess tax benefits recognized on stock option exercises and the vesting of restricted stock units during the period, which is treated as a discrete item and excluded from determining our annual estimated effective tax rate.

### Liquidity and Capital Resources

During the first three months of 2019, our cash, cash equivalents, short-term and long-term investments decreased by $68.9 million from $384.1 million at December 31, 2018 to $315.3 million at March 31, 2019.

### Cash Flows from Operating Activities

Our net cash used in operations for the three months ended March 31, 2019 was $21.0 million. Net income plus adjustments for non-cash net expenses contributed $70.5 million. Net cash used in operations as a result of changes in operating assets and liabilities was $91.5 million. The changes in operating assets and liabilities included a $49.5 million increase in accounts receivable, a $34.8 million decrease in accrued liabilities, a $12.0 million increase in inventories, a $7.5 million increase in other assets and $1.1 million in net changes in income taxes, including excess tax benefits and deferred income taxes. Offsetting these amounts was a $10.3 million decrease in prepaid expenses and other current assets and a $3.1 million increase in accounts payable. The increase in accounts receivable is mainly due to the current year reclassification of receivables from Pfizer and the timing of revenue and collections. In the current year, receivables from Pfizer are included in accounts receivable and not in a separate related-party receivable line item as in the prior year. As of December 31, 2018, Pfizer had sold all of its shares of ICU common stock thereby ending its related-party relationship with ICU. The decrease in accrued liabilities was primarily a result of the payout of accrued compensation. The increase in inventory was primarily due to an increase in our finished goods safety stock. The increase in other assets was primarily related to the purchase of spare parts. The net changes in income taxes was a result of the timing of payments. The decrease in prepaid expenses and other current assets was primarily due to the collection of receivable amounts owed from Pfizer. The increase in accounts payable was due to the timing of payments.

Our net cash used in operations for the three months ended March 31, 2018 was $20.7 million. Net income plus adjustments for non-cash net expenses offset cash used by changes in operating assets and liabilities by $35.8 million. The cash used by changes in operating assets and liabilities was $56.5 million. The changes in operating assets and liabilities included a $29.5 million decrease in accrued liabilities, a $32.8 million increase in related party receivables, a $11.9 million increase in accounts receivable, a $2.3 million increase in other assets and $3.3 million in net changes in income taxes, including excess tax benefits and deferred income taxes. Offsetting these amounts was a $10.9 million decrease in inventories, $3.6 million decrease in prepaid expenses and other assets, and a $8.7 million increase in accounts payable. The decrease in accrued liabilities was primarily a result of the payout of accrued compensation. The increase in related-party receivables was primarily due to the timing of amounts to be received from Pfizer. The increase in accounts receivable is due to the increase in revenue. The decrease in inventory was primarily due to our continued inventory reduction effort. The increase in other assets was primarily related to the purchase of spare parts. The net changes in income taxes was a result of the timing of payments. The decrease in prepaid expenses and other assets was primarily due to the settlement of a deposit on inventory. The increase in accounts payable was due to the timing of payments.

### Cash Flows from Investing Activities

The following table summarizes the changes in our investing cash flows (in thousands):

| Investing Cash Flows: | Three months ended March 31, 2019 | 2018 | Change |  |
| --- | ---: | ---: | ---: | ---: |
| Purchases of property and equipment | $(28,671) | $(26,544) | $(2,127) | (1) |
| Proceeds from sale of assets held-for-sale | — | 13,000 | $(13,000) | (2) |
| Proceeds from sale of assets | 16 | — | 16 |  |
| Intangible asset additions | (1,949) | (1,899) | (50) |  |
| Purchases of investment securities | (4,409) | (4,478) | 69 | (3) |
| Proceeds from sale of investment securities | 24,500 | 4,900 | 19,600 | (4) |
| Net cash used in investing activities | $(10,513) | $(15,021) | $4,508 |  |

(1) Our purchases of property and equipment will vary from period to period based on additional investments needed to support new and existing products and expansion of our manufacturing facilities.

(2) In 2018, we sold the land and building related to our Dominican Republic manufacturing facilities acquired as part of the 2017 HIS acquisition.

(3) Our purchases of investment securities will vary from period to period based on current cash needs, planning for known future transactions and due to changes in our investment strategy.

(4) Proceeds from the sale or maturity of our investment securities will vary from period to period based on the maturity dates of the investments we currently hold.

While we can provide no assurances, we estimate that our capital expenditures in 2019 will be approximately $95.0 million to $105.0 million. We anticipate making additional investments in machinery and equipment in our manufacturing operations in Costa Rica, the U.S. and Mexico to support new and existing products, in infusion products that are placed with customers outside the U.S., and in IT to benefit world-wide operations.

We expect to use our cash to fund our capital purchases. Amounts of spending are estimates and actual spending may substantially differ from those amounts.

### Cash Flows from Financing Activities

The following table summarizes the changes in our financing cash flows (in thousands):

| Financing Cash Flows: | Three months ended March 31, 2019 | 2018 | Change |  |
| --- | ---: | ---: | ---: | ---: |
| Proceeds from exercise of stock options | $925 | $3,155 | $(2,230) | (1) |
| Tax withholding payments related to net share settlement of equity awards | (18,157) | (5,338) | (12,819) | (2) |
| Net cash used in financing activities | $(17,232) | $(2,183) | $(15,049) |  |

(1) Proceeds from the exercise of stock options will vary from period to period based on the volume of options exercised and the exercise price of the specific options exercised.

(2) During the three months ended March 31, 2019, our employees surrendered 77,642 shares of our common stock from vested restricted stock awards as consideration for approximately $18.2 million in minimum statutory withholding obligations paid on their behalf. During the three months ended March 31, 2018, our employees surrendered 23,101 shares of our common stock from vested restricted stock awards as consideration for approximately $5.3 million in minimum statutory withholding obligations paid on their behalf.

In July 2010, our Board of Directors approved a share purchase plan to purchase up to $40.0 million of our common stock. As of March 31, 2019, we had purchased $32.8 million of our common stock pursuant to this plan, leaving a balance of $7.2 million available for future purchases. This plan has no expiration date.

We have a substantial cash and investment security position generated from operations and stock sales, principally from the exercise of employee stock options. We maintain this position to fund our growth, meet increasing working capital requirements, fund capital expenditures and to take advantage of acquisition opportunities that may arise. Our primary investment goal is capital preservation.

#### Access to Capital

We believe that our existing cash and cash equivalents along with funds expected to be generated from future operations will provide us with sufficient funds to finance our current operations for the next twelve months. In the event that we experience downturns or cyclical fluctuations in our business that are more severe or longer than anticipated or if we fail to achieve anticipated revenue and expense levels, we may need to obtain or seek alternative sources of capital or financing, and we can provide no assurances that the terms of such capital or financing will be available to us on favorable terms, if at all. Our ability to generate cash flows from operations, issue debt or enter into other financing arrangements on acceptable terms could be adversely affected if there is a material decline in the demand for our products or in the solvency of our customers or suppliers, deterioration in our key financial ratios or credit ratings or other significantly unfavorable changes in conditions

#### Credit Facility

We have a five-year Senior Secured Revolving Credit Facility ("Credit Facility") with various lenders for $150.0 million, with Wells Fargo Bank, N.A. as the administrative agent (see Note 17: Long-Term Obligations). The Credit Facility has an accordion feature that would enable us to increase the borrowing capacity of the credit facility by the greater of (i) $100.0 million and (ii) 2.00x Total Leverage. Under the terms of the Credit Facility, we will be subject to certain financial covenants pertaining to leverage and fixed charge coverage ratios. Borrowings under the Credit Facility will bear interest at LIBOR plus an applicable margin tied to the leverage ratio in effect. The unused portion of the Credit Facility will be subject to a per annum commitment fee which is also calculated using the leverage ratio in effect. The Credit Facility matures in 2022.

#### Financial Covenants

The Credit Facility contains certain negative financial covenants, including, Consolidated Total Leverage and Consolidated Fixed Charge Coverage Ratios.

The Consolidated Leverage Ratio is defined as the ratio of Consolidated Total Funded Indebtedness on such date, to Consolidated Adjusted EBITDA, as defined under the Credit Facility Agreement, for the most recently completed four fiscal quarters. The maximum Consolidated Leverage Ratio is not more than 3.00 to 1.00.

The Consolidated Fixed Charge Coverage Ratio is defined as the ratio of: (a) Consolidated Adjusted EBITDA less the sum of (i) capital expenditures, (ii) federal, state, local and foreign income taxes paid in cash and (iii) cash restricted payments made after the closing date, to (b) Consolidated Fixed Charges for the most recently completed four fiscal quarters, calculated on a pro forma basis. The minimum Consolidated Fixed Charge Coverage Ratio is 2.00 to 1.00.

We were in compliance with all financial covenants as of March 31, 2019.

### Off Balance Sheet Arrangements

In the normal course of business, we have agreed to indemnify our officers and directors to the maximum extent permitted under Delaware law and to indemnify customers as to certain intellectual property matters related to sales of our products. There is no maximum limit on the indemnification that may be required under these agreements. Although we can provide no assurances, we have never incurred, nor do we expect to incur, any material liability for indemnification.

### Contractual Obligations

There have been no material changes to our contractual obligations disclosed in our Annual Report on FOrm 10-K for the fiscal year ended December 31, 2018 ("Annual Report"). On January 1, 2019, we adopted Accounting Standard Update ("ASU") No. 2016-02, Leases (Topic 842). The impact of the adoption of ASU No. 2016-02 on our operating lease obligations is disclosed in Note 6 to Part I, Item 1. Financial Statements.

### Critical Accounting Policies

In our Annual Report, we identified the critical accounting policies which affect our more significant estimates and assumptions used in preparing our consolidated financial statements, there have been no material changes to our critical accounting policies from those previously disclosed in our Annual Report.

### New Accounting Pronouncements

See Note 2 to Part I, Item 1. Financial Statements.

### Forward Looking Statements

Various portions of this Quarterly Report on Form 10-Q, including this Management’s Discussion and Analysis of Financial Condition and Results of Operations, and documents referenced herein, describe trends in our business and finances that we perceive and state some of our expectations and beliefs about our future. These statements about the future are “forward looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and we may identify them by using words such as "anticipate," "believe," "expect," "estimate," "intend," "plan," "will," "continue," "could," "may," and by similar expressions and statements about aims, goals and plans. The forward looking statements are based on the best information currently available to us and assumptions that we believe are reasonable, but we do not intend the statements to be representations as to future results. They include, without limitation, statements about:

- future growth; future operating results and various elements of operating results, including future expenditures and effects with respect to sales and marketing and product development and acquisition efforts; future sales and unit volumes of products; expected increases and decreases in sales; deferred revenue; accruals for restructuring charges, future license, royalty and revenue share income; production costs; gross margins; litigation expense; future SG&A and R&D expenses; manufacturing expenses; future costs of expanding our business; income; losses; cash flow; amortization; source of funds for capital purchases and

operations; future tax rates; alternative sources of capital or financing; changes in working capital items such as receivables and inventory; selling prices; and income taxes;

- factors affecting operating results, such as shipments to specific customers; reduced dependence on current proprietary products; loss of a strategic relationship; change in demand; domestic and international sales; expansion in international markets, selling prices; future increases or decreases in sales of certain products and in certain markets and distribution channels; maintaining strategic relationships and securing long-term and multi-product contracts with large healthcare providers and major buying organizations; increases in systems capabilities; introduction, development and sales of new products, acquisition and integration of businesses and product lines; benefits of our products over competing systems; qualification of our new products for the expedited Section 510(k) clearance procedure; possibility of lengthier clearance process for new products; planned increases in marketing; warranty claims; rebates; product returns; bad debt expense; amortization expense; inventory requirements; lives of property and equipment; manufacturing efficiencies and cost savings; unit manufacturing costs; establishment or expansion of production facilities inside or outside of the United States; planned new orders for semi-automated or fully automated assembly machines for new products; adequacy of production capacity; results of R&D; our plans to repurchase shares of our common stock; asset impairment losses; relocation of manufacturing facilities and personnel; effect of expansion of manufacturing facilities on production efficiencies and resolution of production inefficiencies; the effect of costs to customers and delivery times; business seasonality and fluctuations in quarterly results; customer ordering patterns and the effects of new accounting pronouncements; and
- new or extended contracts with manufacturers and buying organizations; dependence on a small number of customers; loss of larger distributors and the ability to locate other distributors; growth of our Clave products in future years; design features of Clave products; the outcome of our strategic initiatives; regulatory approvals and compliance; outcome of litigation; patent protection and intellectual property landscape; patent infringement claims and the impact of newly issued patents on other medical devices; competitive and market factors, including continuing development of competing products by other manufacturers; improved production processes and higher volume production; innovation requirements; consolidation of the healthcare provider market and downward pressure on selling prices; distribution or financial capabilities of competitors; healthcare reform legislation; use of treasury stock; working capital requirements; liquidity and realizable value of our investment securities; future investment alternatives; foreign currency denominated financial instruments; foreign exchange risk; commodity price risk; our expectations regarding liquidity and capital resources over the next twelve months; capital expenditures; plans to convert existing space; acquisitions of other businesses or product lines, indemnification liabilities and contractual liabilities.

Forward-looking statements involve certain risks and uncertainties, which may cause actual results to differ materially from those discussed in each such statement. First, one should consider the factors and risks described in the statements themselves or otherwise discussed herein. Those factors are uncertain, and if one or more of them turn out differently than we currently expect, our operating results may differ materially from our current expectations.

Second, investors should read the forward looking statements in conjunction with the Risk Factors discussed in Part I, Item 1A of our Annual Report on Form 10-K with the SEC for the year ended December 31, 2018, Part II, Item 1A of this Quarterly Report on Form 10-Q and our other reports filed with the SEC. Also, actual future operating results are subject to other important factors and risks that we cannot predict or control, including without limitation, the following:

- general economic and business conditions, both in the U.S. and internationally;
- unexpected changes in our arrangements with Pfizer or our other large customers;
- outcome of litigation;
- fluctuations in foreign exchange rates and other risks of doing business internationally;
- increases in labor costs or competition for skilled workers;
- increases in costs or availability of the raw materials need to manufacture our products;
- the effect of price and safety considerations on the healthcare industry;
- competitive factors, such as product innovation, new technologies, marketing and distribution strength and price erosion;
- the successful development and marketing of new products;
- unanticipated market shifts and trends;
- the impact of legislation affecting government reimbursement of healthcare costs;
- changes by our major customers and independent distributors in their strategies that might affect their efforts to market our products;
- the effects of additional governmental regulations;
- unanticipated production problems; and
- the availability of patent protection and the cost of enforcing and of defending patent claims.

The forward-looking statements in this report are subject to additional risks and uncertainties, including those detailed from time to time in our other filings with the Securities and Exchange Commission. These forward-looking statements are made only as of the date hereof and, except as required by law, we undertake no obligation to update or revise any of them, whether as a result of new information, future events or otherwise.

## Market risk

As filed, 1,760 characters.

#### Interest rate risk

If we were to incur borrowings under our Credit Facility, we would face market risk stemming from changes in interest rates.

#### Foreign Exchange Risk

We have foreign currency exchange risk related to foreign-denominated cash, accounts receivable and accounts payable and accrued liabilities.

In our European operations, our net Euro asset position at March 31, 2019 was approximately €58.3 million. A 10% change in the conversion of the Euro to the U.S. dollar for our cash, accounts receivable, accounts payable and accrued liabilities from the March 31, 2019 spot rate would impact our consolidated amounts on these balance sheet items by approximately $6.5 million, or 2.2% of these consolidated net assets. We expect that in the future, with the growth of our European distribution operations, net Euro denominated instruments will continue to increase. In our Canadian operations, our net Canadian dollar asset position at March 31, 2019 was approximately $43.0 million. A 10% change in the conversion of the Canadian dollar to the U.S. dollar for our cash, accounts receivable, accounts payable and accrued liabilities from the March 31, 2019 spot rate would impact our consolidated amounts on these balance sheet items by approximately $3.2 million, or 1.1% of these net assets. We currently do not hedge our Canadian dollar or Euro foreign currency exposures.

We have manufacturing facilities and conduct business transactions denominated in the Mexican Peso. We hedge a portion of our manufacturing spend, which reduces our exposure to the foreign currency exchange risk related to the Mexican Peso (see Note 8, Derivatives and Hedging to the condensed consolidated financial statements in Part I, Item 1 of this Form 10-Q).

## Controls and procedures

As filed, 1,124 characters.

#### Evaluation of Disclosure Controls and Procedures

Our principal executive officer and principal financial officer have concluded, based on their evaluation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act")), as of the end of the period covered by this Report, that our disclosure controls and procedures are effective to ensure that the information we are required to disclose in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure and that such information is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC.

There was no change in our internal control over financial reporting during the quarter ended March 31, 2019 that has materially affected or is reasonably likely to materially affect our internal control over financial reporting.

## Risk factors

As filed, 385 characters.

In evaluating an investment in our common stock, investors should consider carefully, among other things, the risk factors previously disclosed in Part I, Item 1A of our Annual Report on Form 10-K filed with the SEC for the year ended December 31, 2018, as well as the information contained in this Quarterly Report and our other reports and registration statements filed with the SEC.

Filed May 10, 2019.
Source: SEC EDGAR, the filing index for accession 0000883984-19-000017. Last ingested by Listed: Nov 14, 2026, 20:54 ET. No prices; not investment advice.
